Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

This study is comparing two drugs — dapagliflozin (an SGLT2 inhibitor commonly used for diabetes and heart failure) and acetazolamide (a diuretic) — for removing excess fluid in hospitalized patients with acute heart failure. Both are added on top of standard IV diuretic treatment to see which works better at relieving congestion. **You may be eligible if...** - You are 18 or older - You are hospitalized for heart failure with significant fluid overload (swelling, weight gain, shortness of breath) - You were randomized within 24 hours of admission - Your kidney function is adequate (eGFR ≥ 30) **You may NOT be eligible if...** - You have Type 1 diabetes - Your blood pressure is dangerously low (systolic < 90 mmHg) - Your shortness of breath is mainly from a non-heart cause - You are in cardiogenic shock or had a recent heart attack (within 30 days) Talk to your doctor to see if this trial is right for you.